\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationHybrid
The European Cancer Summit 2024 aims to unite the cancer community in accelerating efforts against the disease. Experts, patients and policymakers will explore new innovative solutions to pressing challenges faced by healthcare systems across Europe and propose new opportunities in cancer research.
The Summit will showcase what is possible when we put aside our differences and work together for more effective, efficient, and equitable cancer care throughout Europe. The theme of this year’s Summit is United Against Cancer: Forging New Frontiers. Among the speakers are Stella Kyriakides, European Commissioner for health and food safety, several members of European Parliament as well as several members of the EU Cancer Mission board.
More information and registration on the event webpage. This is a hybrid event, taking place in Brussels and online. Note that it is a paying event.
The European Cancer Summit will be followed by a Showcase Event for the smartCARE and PROTECT-EUROPE projects on 22 November, at the same venue. Find out more here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
